Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker GLUE
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Aaron Cowen | 3.55M | 4.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Averill Master Fund, Ltd. | 3.22M | 3.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Montanova Capital, LLC | 3.55M | 4.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G | GLUE Monte Rosa Therapeutics, Inc. | Ryan Wilder | 4.60M | 5.4% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | GLUE Monte Rosa Therapeutics, Inc. | Vestal Point Capital, LP | 4.60M | 5.4% | SCHEDULE 13G ↗ |
| Jul 8, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | T. Rowe Price Associates, Inc. | 8.86M | 10.5% | SCHEDULE 13G/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Rick Yang | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Paul Walker | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Edward T. Mathers | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Carmen Chang | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Ali Behbahani | 135,432 | 0.2% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Forest Baskett | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Scott D. Sandell | 6.69M | 7.9% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Mohamad H. Makhzoumi | 6.69M | 7.9% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Anthony A. Florence, Jr. | 6.69M | 7.9% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Nea 17 GP, LLC | 6.69M | 7.9% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | NEA Partners 17, L.P. | 6.69M | 7.9% | SCHEDULE 13D/A ↗ |
| Jul 6, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | New Enterprise Associates 17, L.P. | 6.69M | 7.9% | SCHEDULE 13D/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Chen Yu | 4.62M | 5.5% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | TCG Crossover Fund III, L.P. | 2.31M | 2.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | TCG Crossover GP III, LLC | 2.31M | 2.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | TCG Crossover Fund II, L.P. | 2.31M | 2.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | TCG Crossover GP II, LLC | 2.31M | 2.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Felix J. Baker | 8.88M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Julian C. Baker | 8.88M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Baker Bros. Advisors (GP) LLC | 8.88M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Baker Bros. Advisors LP | 8.88M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Mark N. Lampert | 5.09M | 6.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | BVF Inc/Il | 5.09M | 6.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | BVF Partners L P/Il | 5.09M | 6.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | BVF GP Holdings LLC | 4.70M | 5.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | BVF Partners OS Ltd. | 306,361 | 0.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Biotechnology Value Trading Fund OS LP | 306,361 | 0.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | BVF II GP LLC | 1.99M | 2.5% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Biotechnology Value Fund II LP | 1.99M | 2.5% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | BVF I GP LLC | 2.72M | 3.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Biotechnology Value Fund L P | 2.72M | 3.4% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Dimension Capital II GP, LLC | 850,500 | 1.1% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Dimension Capital II, L.P. | 850,500 | 1.1% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Dimension Capital I, L.P. | 5.66M | 7.1% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Dimension Management GP, LLC | 6.51M | 8.1% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Dimension Capital I GP, LLC | 5.66M | 7.1% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Dimension Management, L.P. | 6.51M | 8.1% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Nan Li | 6.51M | 8.1% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Zavain Dar | 6.51M | 8.1% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Adam Goulburn | 6.51M | 8.1% | SCHEDULE 13G/A ↗ |
| Mar 19, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Rick Yang | 7.69M | 9.6% | SCHEDULE 13D/A ↗ |
| Mar 19, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Paul Walker | 7.69M | 9.6% | SCHEDULE 13D/A ↗ |
| Mar 19, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Scott D. Sandell | 7.69M | 9.6% | SCHEDULE 13D/A ↗ |
| Mar 19, 2026 | SCHEDULE 13D/A (amended) | GLUE Monte Rosa Therapeutics, Inc. | Edward T. Mathers | 7.69M | 9.6% | SCHEDULE 13D/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances